Borealis Biosciences has been launched by Novartis and venture capital company Versant Ventures, with a focus on next-generation RNA medicines to treat kidney disease. "Novartis is committed to bringing forward new therapeutic options for patients with kidney diseases," said Fiona Marshall, president of Novartis' Biomedical Research.